Cite
MLA Citation
Gary Berman et al.. “Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.” Headache, vol. 60, no. 8, 2020, pp. 1734–1742. http://access.bl.uk/ark:/81055/vdc_100107622899.0x00005c